Share this Page:
A study involving 45,824 patients newly diagnosed with renal cell carcinoma (RCC), of which 1509 (3.29%) had bone metastases upon initial diagnosis, was recently reported in Cancer Management and Research.
The researchers identified older age, male sex, lymph node involvement, and higher T stage among the risk factors for bone metastases at the initial diagnosis of RCC.
The incidence of bone metastases was 3.87%, 1.52%, 0.80%, and 18.1% among patients with clear-cell, papillary, chromophobe, and collecting duct RCC, respectively.
To help improve the management of patients with RCC and bone metastases and to improve patient outcomes, global experts have come together to review and discuss current treatment pathways based on their expertise and published data. In this paper, the experts recommend strategies for the diagnosis and treatment of people with RCC bone metastases. They also discuss current challenges in the management of these patients, and highlight unmet patient needs that warrant further research.